KMT2D

Across TCGA pan-cancer cohorts, KMT2D RNA differs between tumor and matched normal tissue in 7 of 18 cancer types tested, making tumor–normal expression one of KMT2D’s most consistent transcriptional readouts.

The strongest signal is observed in liver hepatocellular carcinoma (LIHC), where KMT2D RNA is more highly expressed in tumor relative to normal tissue. In most cancer types KMT2D is over-expressed in tumor, although a few such as THCA show the opposite, repressed pattern.

LIHC, THCA, and STAD are the cancer types where KMT2D tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in KMT2D RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
LIHC	Female	II,III,IV	+1.265	<.001	7	view →
THCA	All	All	−0.504	<.001	7	view →
STAD	All	II,III,IV	+1.002	<.001	6	view →
HNSC	All	II,III,IV	+0.538	<.001	6	view →
CHOL	Male	All	+2.085	<.001	5	view →
PRAD	All	All	+0.468	.002	2	view →
ESCA	Female	All	+0.606	.007	1	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 7 strongest of 7 lineages.

KMT2D–LIHC

Open the LIHC breakdown →